Brian Freed

Company: RheumaGen

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Introducing Genetic Tolerance Through HLA Gene Editing: Evaluating the Preclinical Data & Regulatory Feedback 2:45 pm

Identifying antigen-specific HLA gene-editing targets with bioinformatics and novel assays Editing the HLA gene without immunosuppression or rejection Reviewing the preclinical data and FDA feedback for Rheumagen’s lead indication of treatment-resistant rheumatoid arthritisRead more

day: Conference Day Two